New vaccine combo aims to stop pancreatic cancer return after surgery
NCT ID NCT06353646
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a personalized cancer vaccine (XH001) given after surgery for pancreatic cancer, followed by immunotherapy drugs (ipilimumab, sintilimab) and chemotherapy (gemcitabine + capecitabine). The goal is to see if this combination can prevent the cancer from coming back. The trial will enroll 28 adults who have had their tumor completely or nearly completely removed and have not had prior treatment. Researchers will track how long patients stay cancer-free and monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XH001 (neoantigen cancer vaccine), ipilimumab, sintilimab, gemcitabine, capecitabine
What this could lead to
If it works, this combination could help prevent pancreatic cancer from coming back after surgery, potentially extending survival.
What could go wrong
This is a very small, early-phase trial with only 28 people, so results may not apply broadly. The treatment involves multiple drugs with significant side effects, and the vaccine is experimental.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact Email: •••••@•••••